Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation on Saturday, December 7th –– ...
Medindia10mon
Menin Gene Mutation made Insulin Secreting Cells to Proliferate
Acute loss of a protein named menin – involved in tumor-suppression or cell-proliferation-suppressing function resulted in the proliferation of pancreatic islet cells, which again affected blood ...
Yahoo Finance1mon
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
About Ziftomenib Ziftomenib is a novel, once-daily, oral investigational drug candidate targeting the menin-KMT2A/MLL protein-protein interaction for treatment of genetically defined AML patients ...
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) ...
Cure Today29d
Revumenib May Have Benefits for Patients with R/R KMT2Ar Acute Leukemia
Researchers noted that rearrangements of the KMT2A gene occur in up to 10% of acute leukemias and that the protein menin plays a crucial role in the development of KMT2Ar leukemia. Revumenib is an ...
Santé log16d
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
Icovamenib is an oral covalent menin inhibitor in clinical development to investigate ... A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers ...